132 related articles for article (PubMed ID: 37807695)
1. Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance.
Matsubara N; Matsuyama H; Kazama H; Seto T; Sunaga Y; Suzuki K
Jpn J Clin Oncol; 2024 Jan; 54(1):97-102. PubMed ID: 37807695
[TBL] [Abstract][Full Text] [Related]
2. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
Matsuyama H; Matsubara N; Kazama H; Seto T; Sunaga Y; Suzuki K
BMC Cancer; 2023 Jun; 23(1):538. PubMed ID: 37308888
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Suzuki K; Matsubara N; Kazama H; Seto T; Tsukube S; Matsuyama H
Jpn J Clin Oncol; 2019 Dec; 49(12):1157-1163. PubMed ID: 31361807
[TBL] [Abstract][Full Text] [Related]
5. Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry.
Malik Z; Di Lorenzo G; Pichler A; De Giorgi U; Hitier S; Ecstein-Fraisse E; Ozatilgan A; Carles J
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32316580
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
Kazama H; Kawaguchi O; Seto T; Suzuki K; Matsuyama H; Matsubara N; Tajima Y; Fukao T
BMC Cancer; 2022 Apr; 22(1):470. PubMed ID: 35484517
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m
Matsuyama H; Matsubara N; Kazama H; Seto T; Tsukube S; Suzuki K
BMC Cancer; 2020 Jul; 20(1):649. PubMed ID: 32660451
[TBL] [Abstract][Full Text] [Related]
9. Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
Thiery-Vuillemin A; Fizazi K; Sartor O; Oudard S; Bury D; Ozatilgan A; Poole EM; Eisenberger M; de Bono J
Oncologist; 2021 Jul; 26(7):e1179-e1188. PubMed ID: 33904646
[TBL] [Abstract][Full Text] [Related]
10. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
12. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T; Uemura H; Sumitomo M; Harada K; Sugimoto M; Hayashi N; Yoshimura K; Fukasawa S; Ecstein-Fraisse E; Sunaga Y; Oya M
Jpn J Clin Oncol; 2019 Aug; 49(8):766-771. PubMed ID: 31329922
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan.
Yamamoto Y; Ishii M; Yoshimura A; Hayashi T; Kawamura N; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Urol; 2023 Jan; 30(1):20-27. PubMed ID: 36168966
[TBL] [Abstract][Full Text] [Related]
14. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.
Hammerer P; Al-Batran SE; Windemuth-Kieselbach C; Keller M; Hofheinz RD
World J Urol; 2018 Mar; 36(3):375-381. PubMed ID: 29305637
[TBL] [Abstract][Full Text] [Related]
15. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
16. [
Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
[TBL] [Abstract][Full Text] [Related]
17. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
18. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
[TBL] [Abstract][Full Text] [Related]
19. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
[TBL] [Abstract][Full Text] [Related]
20. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Med Oncol; 2017 Aug; 34(8):141. PubMed ID: 28718092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
